Recently, two relapsed/refractory AML patients who received HSCT and CD38-CAR-T cell therapy before showed continuous remission after receiving PD-1-silenced CLL-1-CAR-T cell therapy (45). Here, CLEC12A is linked to acute myeloid leukemia.